Tenvie Therapeutics raised $200 million to develop small molecules for treating neurological disorders.
Tenvie Therapeutics raised $200 million to develop small molecules for treating neurological disorders.
01/08/25, 9:58 PM
Location
south san franciscoMoney raised
$200 million
Industry
therapeutics
biotechnology
health care
Tenvie Therapeutics secured $200 million in its debut financing round, making it the largest raise among the recent batch of biotech funding. This financing aims to support the development of their innovative treatments for neurological disorders.
Company Info
Location
south san francisco, california, united states
Additional Info
Tenvie is a biotechnology company committed to engineering small molecules that transform the treatment of neurological diseases. The company’s foundation is purpose-built with a diverse portfolio of small molecules and a proven team of CNS drug developers to rapidly deliver multiple clinical assets. Tenvie is advancing a pipeline of therapeutics focused on treating neurological, cardiometabolic, and ophthalmic diseases. Its portfolio of wholly owned, highly brain-penetrant, and precision-designed peripherally restricted small molecules address three key drivers of disease: resolving inflammation, rescuing metabolic dysfunction, and restoring lysosomal function. The company’s most advanced programs target NLRP3 and SARM1, with additional programs in preclinical development.